Cargando…
Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets
For acute myeloid leukemia (AML), identification of activating mutations in the FMS-like tyrosine kinase-3 (FLT3) has led to the development of several FLT3-inhibitors. Here we present clinical and next generation sequencing data at the time of progression of a patient on a novel FLT3-inhibitor clin...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4726703/ https://www.ncbi.nlm.nih.gov/pubmed/26904404 http://dx.doi.org/10.1016/j.lrr.2016.01.002 |
_version_ | 1782411870996529152 |
---|---|
author | Kasi, Pashtoon M. Litzow, Mark R. Patnaik, Mrinal M. Hashmi, Shahrukh K. Gangat, Naseema |
author_facet | Kasi, Pashtoon M. Litzow, Mark R. Patnaik, Mrinal M. Hashmi, Shahrukh K. Gangat, Naseema |
author_sort | Kasi, Pashtoon M. |
collection | PubMed |
description | For acute myeloid leukemia (AML), identification of activating mutations in the FMS-like tyrosine kinase-3 (FLT3) has led to the development of several FLT3-inhibitors. Here we present clinical and next generation sequencing data at the time of progression of a patient on a novel FLT3-inhibitor clinical trial (ASP2215) to show that employing therapeutic interventions with these novel targeted therapies can lead to consequences secondary to selective pressure and clonal evolution of cancer. We describe novel findings alongside data on treatment directed towards actionable aberrations acquired during the process. (Clinical Trial: NCT02014558; registered at: 〈https://clinicaltrials.gov/ct2/show/NCT02014558〉) |
format | Online Article Text |
id | pubmed-4726703 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-47267032016-02-22 Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets Kasi, Pashtoon M. Litzow, Mark R. Patnaik, Mrinal M. Hashmi, Shahrukh K. Gangat, Naseema Leuk Res Rep Article For acute myeloid leukemia (AML), identification of activating mutations in the FMS-like tyrosine kinase-3 (FLT3) has led to the development of several FLT3-inhibitors. Here we present clinical and next generation sequencing data at the time of progression of a patient on a novel FLT3-inhibitor clinical trial (ASP2215) to show that employing therapeutic interventions with these novel targeted therapies can lead to consequences secondary to selective pressure and clonal evolution of cancer. We describe novel findings alongside data on treatment directed towards actionable aberrations acquired during the process. (Clinical Trial: NCT02014558; registered at: 〈https://clinicaltrials.gov/ct2/show/NCT02014558〉) Elsevier 2016-01-12 /pmc/articles/PMC4726703/ /pubmed/26904404 http://dx.doi.org/10.1016/j.lrr.2016.01.002 Text en © 2016 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Kasi, Pashtoon M. Litzow, Mark R. Patnaik, Mrinal M. Hashmi, Shahrukh K. Gangat, Naseema Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets |
title | Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets |
title_full | Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets |
title_fullStr | Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets |
title_full_unstemmed | Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets |
title_short | Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets |
title_sort | clonal evolution of aml on novel fms-like tyrosine kinase-3 (flt3) inhibitor therapy with evolving actionable targets |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4726703/ https://www.ncbi.nlm.nih.gov/pubmed/26904404 http://dx.doi.org/10.1016/j.lrr.2016.01.002 |
work_keys_str_mv | AT kasipashtoonm clonalevolutionofamlonnovelfmsliketyrosinekinase3flt3inhibitortherapywithevolvingactionabletargets AT litzowmarkr clonalevolutionofamlonnovelfmsliketyrosinekinase3flt3inhibitortherapywithevolvingactionabletargets AT patnaikmrinalm clonalevolutionofamlonnovelfmsliketyrosinekinase3flt3inhibitortherapywithevolvingactionabletargets AT hashmishahrukhk clonalevolutionofamlonnovelfmsliketyrosinekinase3flt3inhibitortherapywithevolvingactionabletargets AT gangatnaseema clonalevolutionofamlonnovelfmsliketyrosinekinase3flt3inhibitortherapywithevolvingactionabletargets |